Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to 0.83%.

  • Xeris Biopharma Holdings' EBITDA Margin rose 2981.00% to 0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.88%, marking a year-over-year increase of 2779.00%. This contributed to the annual value of -27.00% for FY2024, which is 1098.00% up from last year.
  • Xeris Biopharma Holdings' EBITDA Margin amounted to 0.83% in Q3 2025, which was up 130.95% from -2.69% recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' EBITDA Margin peaked at 0.83% during Q3 2025, and registered a low of -309.06% during Q2 2021.
  • In the last 3 years, Xeris Biopharma Holdings' EBITDA Margin had a median value of -28.97% in 2024 and averaged -26.45%.
  • In the last 5 years, Xeris Biopharma Holdings' EBITDA Margin plummeted by 6,393bps in 2021 and then surged by 20,564bps in 2022.
  • Xeris Biopharma Holdings' EBITDA Margin (Quarterly) stood at -237.04% in 2021, then soared by 19,807bps to -38.97% in 2022, then spiked by 886bps to -30.11% in 2023, then surged by 2,159bps to -8.52% in 2024, then soared by 2,981bps to 0.83% in 2025.
  • Its EBITDA Margin stands at 0.83% for Q3 2025, versus -2.69% for Q2 2025 and -15.34% for Q1 2025.